We studied the antimicrobacterial activity and clinical efficacy of balofloxacin (BLFX), a new quinolone, in the urological field. 1) Antibacterial activity: The MICs of BLFX were measured against 210 clinical isolates of 14 species from urinary tract infections and compared with those of ofloxacin (OFLX) and norfloxacin (NFLX). In general, the antibacterial activity of BLFX was inferior to that of OFLX, but almost equal to that of NFLX. 2) Clinical efficacy: According to the criteria of the Japanese UTI Committee, the overall efficacy rate was 80.0% (4/5) for chronic complicated UTI. Bacteriologically, eleven of the 12 strains isolated (91.7%) were eradicated. 3)Side effects: No clinical adverse reactions anti no abnormal laboratory findings were observed.
|Number of pages||6|
|Journal||Japanese Journal of Chemotherapy|
|Issue number||SUPPL. 5|
|Publication status||Published - Dec 1 1995|
ASJC Scopus subject areas
- Pharmacology (medical)